Phase 3 Type 2 diabetes trials recruiting now

All Type 2 diabetes trials, every phase

Other phases for Type 2 diabetes

Phase 3 Type 2 diabetes trials

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 203 locations
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 204 locations
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 650 locations
• A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
  NCT07082114 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
  NCT07662044 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 149 locations
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
  NCT07662135 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 186 locations
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
  NCT07664553 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 132 locations
• A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
  NCT07662109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 272 locations
• A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
  NCT07165223 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
  NCT06647745 · Phase: Phase 3 · Ages: 19 Years and older · Sex: All (male and female) · 2 locations
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 303 locations
• A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
  NCT07282613 · Phase: Phase 3 · Ages: 10 Years to 18 Years · Sex: All (male and female) · 58 locations
• A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
  NCT04786262 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 29 locations
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · 74 locations
• A Study of Apabetalone in Subjects With Long -COVID
  NCT06590324 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of BGM0504 in Early T2DM With Obesity
  NCT07743983 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
  NCT07064486 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 4 locations
• A Study of BGM0504 in Participants with Type 2 Diabetes
  NCT06716216 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
  NCT06716203 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
  NCT06739122 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · 51 locations
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 157 locations
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 324 locations
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 374 locations
• A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
  NCT07394114 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 135 locations
• A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
  NCT07613307 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 40 locations
• A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
  NCT07776509 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 96 locations
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 212 locations
• A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
  NCT07379333 · Phase: Phase 3 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
  NCT07219602 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
  NCT07670416 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
  NCT07662213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 209 locations
• A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
  NCT07775404 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 98 locations
• A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
  NCT07595549 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 100 locations
• A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
  NCT07754461 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 121 locations
• AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
  NCT07533175 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 74 locations
• AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
  NCT07797335 · Phase: Phase 3 · Ages: 45 Years and older · Sex: All (male and female) · 330 locations
• COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
  NCT05633810 · Phase: Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female) · 39 locations
• Canagliflozin Targeting Vascular Inflammation
  NCT05427084 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes
  NCT06989697 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female) · 1 location
• Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
  NCT07552389 · Phase: Phase 3 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
  NCT06246799 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial
  NCT05211375 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1147 locations
• Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
  NCT07581145 · Phase: Phase 3 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Effect of a Healthy Food Voucher on Blood Glucose Control in People With Type 2 Diabetes or Prediabetes
  NCT05776420 · Phase: Phase 3 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
  NCT07093476 · Phase: Phase 3 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
  NCT04602754 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes
  NCT07279194 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
  NCT07060456 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
  NCT04670666 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
  NCT05028140 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
  NCT07481747 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia
  NCT06772168 · Phase: Phase 3 · Ages: 19 Years to 80 Years · Sex: All (male and female) · 24 locations
• Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
  NCT07527078 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Exercise and Intranasal Insulin in Type 2 Diabetes
  NCT07675499 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female) · 4 locations
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
  NCT07684144 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 74 locations
• Fecal Microbiota Transfer to Improve Diabetes Control Post-bariatric Surgery
  NCT06192693 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Impact of P53 and SIRT1 in Type 2 Diabetes
  NCT03925714 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes
  NCT07428746 · Phase: Phase 3 · Ages: 65 Years and older · Sex: Female · 1 location
• KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
  NCT06451757 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
  NCT06361238 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female) · 1 location
• Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
  NCT07083154 · Phase: Phase 3 · Ages: 50 Years to 75 Years · Sex: All (male and female) · 8 locations
• Olive Leaf Extracts in the Control of Diabet
  NCT05605704 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）
  NCT07659574 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
  NCT07653477 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• RCT Glargine vs NPH for Treatment of DM in Pregnancy
  NCT06619301 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · 1 location
• SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
  NCT05345327 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Semaglutide for Smoking Cessation in Patients With Diabetes
  NCT07059377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
  NCT05569772 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · 13 locations
• Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
  NCT07193459 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Vitamin D and Type 2 Diabetes - Treat-To-Target
  NCT07448974 · Phase: Phase 3 · Ages: 30 Years to 74 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.